Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

RenovoRx, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MOUNTAIN VIEW, CALIF., DEC. 11, 2025 (GLOBE NEWSWIRE) -- RENOVORX, INC.

RENOVORX ANNOUNCES ACCEPTANCE OF CLINICAL DATA ABSTRACT AT THE ASCO GASTROINTESTINAL CANCERS SYMPOSIUM 2026

MOUNTAIN VIEW, CALIF., DEC. 01, 2025 (GLOBE NEWSWIRE) -- RENOVORX, INC. (NASDAQ: RNXT)(RENOVORX OR THE COMPANY), A LIFE SCIENCES COMPANY DEVELOPING INNOVATIVE TARGETED ONCOLOGY THERAPIES AND COMMERCIALIZING RENOVOCATH  , A NOVEL, FDA-CLEARED DRUG-DELIVERY DEVICE, TODAY ANNOUNCED THAT CHIEF EXECUTIVE OFFICER SHAUN BAGAI WILL PRESENT AT THE IACCESS ALPHA VIRTUAL BEST IDEAS WINTER INVESTMENT CONFERENCE 2025, HELD ON DECEMBER 9-10, 2025. MR. BAGAI'S PRESENTATION WILL BE HELD ON TUESDAY, DECEMBER 9TH AT 12:30 P.M. ET.

RENOVORX CEO SHAUN BAGAI TO PRESENT AT IACCESS ALPHA VIRTUAL BEST IDEAS WINTER INVESTMENT CONFERENCE 2025 ON DECEMBER 9TH

MOUNTAIN VIEW, CALIF., NOV. 19, 2025 (GLOBE NEWSWIRE) -- RENOVORX, INC. (NASDAQ: RNXT)(RENOVORX OR THE COMPANY), A LIFE SCIENCES COMPANY DEVELOPING INNOVATIVE TARGETED ONCOLOGY THERAPIES AND COMMERCIALIZING RENOVOCATH, A NOVEL, FDA-CLEARED DRUG-DELIVERY DEVICE, TODAY ANNOUNCED THAT CHIEF EXECUTIVE OFFICER SHAUN BAGAI WILL PARTICIPATE IN THE ALLIANCE GLOBAL PARTNERS (AGP) EMERGING AGBIOTECH/BIO-SOLUTIONS VIRTUAL SHOWCASE. THE EVENT WILL BE HOSTED BY SCOTT HENRY, MANAGING DIRECTOR AND HEALTHCARE ANALYST, AT AGP ON NOVEMBER 20TH, 2025.

RENOVORX CEO SHAUN BAGAI TO PRESENT AT THE ALLIANCE GLOBAL PARTNERS EMERGING AGBIOTECH/BIO-SOLUTIONS VIRTUAL SHOWCASE ON NOVEMBER 20TH

SEPTEMBER 30, 2025 CASH AND CASH EQUIVALENTS AT $10 MILLION REVENUE EXPECTED TO GROW IN 2026 AND CONTINUE TO OFFSET CASH BURN MANAGEMENT TO HOST CONFERENCE CALL TODAY AT 4:30 P.M. ET MOUNTAIN VIEW, CALIF.

RENOVORX REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS, INCLUDING APPROXIMATELY $900,000 IN YEAR-TO-DATE REVENUE, AND PROVIDES BUSINESS UPDATE

COMPANY APPOINTS DISTINGUISHED UCLA ONCOLOGY SURGEON TO SAB, ENHANCING BOARD'S EXPERTISE IN SURGICAL ONCOLOGY AND TRANSLATIONAL ONCOLOGY RESEARCH AIMED AT IMPROVING MULTIDISCIPLINARY TREATMENT STRATEGIES COMPANY APPOINTS DISTINGUISHED UCLA ONCOLOGY SURGEON TO SAB, ENHANCING BOARD'S EXPERTISE IN SURGICAL ONCOLOGY AND TRANSLATIONAL ONCOLOGY RESEARCH AIMED AT IMPROVING MULTIDISCIPLINARY TREATMENT STRATEGIES

RENOVORX STRENGTHENS SCIENTIFIC ADVISORY BOARD (SAB) WITH PANCREATIC CANCER EXPERT TIMOTHY DONAHUE, MD

MOUNTAIN VIEW, CALIF., NOV. 04, 2025 (GLOBE NEWSWIRE) -- RENOVORX, INC . (RENOVORX OR THE COMPANY) (NASDAQ: RNXT), A LIFE-SCIENCES COMPANY DEVELOPING INNOVATIVE TARGETED ONCOLOGY THERAPIES AND COMMERCIALIZING RENOVOCATH  , A PATENTED, FDA-CLEARED DRUG-DELIVERY DEVICE, TODAY ANNOUNCED THAT SHAUN BAGAI, CHIEF EXECUTIVE OFFICER, WILL BE PARTICIPATING AT THE CANACCORD GENUITY MEDTECH, DIAGNOSTICS & DIGITAL HEALTH & SERVICES FORUM, TO BE HELD ON NOVEMBER 20, 2025.

RENOVORX CEO SHAUN BAGAI TO PARTICIPATE AT THE CANACCORD GENUITY MEDTECH, DIAGNOSTICS & DIGITAL HEALTH & SERVICES FORUM ON NOVEMBER 20TH

MOUNTAIN VIEW, CALIF., OCT. 27, 2025 (GLOBE NEWSWIRE) -- RENOVORX, INC. (RENOVORX OR THE COMPANY) (NASDAQ: RNXT), A LIFE SCIENCES COMPANY DEVELOPING INNOVATIVE TARGETED ONCOLOGY THERAPIES AND COMMERCIALIZING RENOVOCATH  , A NOVEL, FDA-CLEARED DRUG-DELIVERY DEVICE, TODAY ANNOUNCED THAT IT WILL HOST ITS THIRD QUARTER 2025 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS CONFERENCE CALL ON NOVEMBER 13, 2025, AT 4:30 P.M.

RENOVORX TO HOST THIRD QUARTER 2025 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS CONFERENCE CALL ON NOVEMBER 13TH AT 4:30 P.M. ET

LOS ALTOS, CALIF., OCT. 09, 2025 (GLOBE NEWSWIRE) -- RENOVORX, INC.

RENOVORX EXPANDS SCIENTIFIC ADVISORY BOARD WITH INTERNATIONALLY RENOWNED INTERVENTIONAL ONCOLOGIST, THIERRY DE BARE, MD, PHD

FIRST REGISTRY-ELIGIBLE PATIENT PROCEDURE COMMENCED AT THE UNIVERSITY OF VERMONT CANCER CENTER BAPTIST HEALTH MIAMI CANCER INSTITUTE AND UNIVERSITY OF PITTSBURGH MEDICAL CENTER JOIN THE UNIVERSITY OF VERMONT CANCER CENTER AS PARTICIPATING CLINICAL SITES THE PANTHER STUDY IS GATHERING EXPANDED SAFETY AND PERFORMANCE DATA OF THE FDA-CLEARED RENOVOCATH  DEVICE AND ITS ASSOCIATED SURVIVAL OUTCOMES IN PATIENTS DIAGNOSED WITH SOLID TUMORS MOUNTAIN VIEW, CALIF., SEPT. 25, 2025 (GLOBE NEWSWIRE) -- RENOVORX, INC.

RENOVORX'S PANTHER POST-MARKETING REGISTRY STUDY PROGRESSES WITH FIRST CLINICAL PROCEDURE AND ADDITION OF TWO PARTICIPATING CLINICAL SITES

MOUNTAIN VIEW, CALIF., SEPT. 11, 2025 (GLOBE NEWSWIRE) -- RENOVORX, INC . (RENOVORX OR THE COMPANY) (NASDAQ: RNXT), A LIFE SCIENCES COMPANY DEVELOPING INNOVATIVE TARGETED ONCOLOGY THERAPIES AND COMMERCIALIZING RENOVOCATH  , A PATENTED, FDA-CLEARED DRUG-DELIVERY DEVICE, TODAY ANNOUNCED THAT SHAUN BAGAI, CHIEF EXECUTIVE OFFICER, WILL PRESENT AT THE IACCESS ALPHA VIRTUAL BEST IDEAS FALL INVESTMENT CONFERENCE 2025, HELD ON SEPTEMBER 16-17, 2025.

RenovoRx, Inc.

RNXT

Price

Financials Overview

Financial Reports

No items found.

Press Releases

RenovoRx, Inc.

RNXT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

RNXT